Scarica l'app Stockscreener
1.63
3.85%
-0.06
Precedente Chiudi:
$1.69
Aprire:
$1.72
Volume 24 ore:
158.03K
Relative Volume:
0.36
Capitalizzazione di mercato:
$197.06M
Reddito:
-
Utile/perdita netta:
$-19.57M
Rapporto P/E:
-0.5208
EPS:
-3.13
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
-7.14%
1M Prestazione:
-18.75%
6M Prestazione:
-8.19%
1 anno Prestazione:
-41.12%
Intervallo 1D:
$1.62
$1.72
Intervallo di 1 settimana:
$1.62
$1.875
Portata 52W:
$1.33
$3.32
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Nome
Inhibikase Therapeutics Inc
Settore
Industria
Telefono
(302) 295-3800
Indirizzo
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Confronta IKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.625 | 204.94M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.73 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.98 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
848.66 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.04 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.18 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-21 | Iniziato | BofA Securities | Buy |
| 2025-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Aug Closing: What is the next catalyst for Inhibikase Therapeutics IncTrade Risk Summary & Community Driven Trade Alerts - baoquankhu1.vn
Risk Report: Does Inhibikase Therapeutics Inc stock benefit from AI growth2025 Market Outlook & Smart Investment Allocation Insights - baoquankhu1.vn
Market Outlook: Is HCA Healthcare Inc stock a smart retirement pickJuly 2025 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What drives Inhibikase Therapeutics Inc.’s stock priceQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq
BofA Securities initiates coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America - MarketBeat
B of A Securities Initiates Coverage on IKT with 'Buy' Rating | - GuruFocus
BofA Securities initiates coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What analyst consensus says on Inhibikase Therapeutics Inc. stockQuarterly Profit Report & Expert Curated Trade Ideas - bollywoodhelpline.com
Can Inhibikase Therapeutics Inc. stock sustain free cash flow growthMarket Growth Report & Daily Stock Momentum Reports - bollywoodhelpline.com
RSI Check: Does Inhibikase Therapeutics Inc outperform in volatile marketsMarket Growth Report & High Accuracy Investment Signals - baoquankhu1.vn
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2%What's Next? - MarketBeat
Take Profit: Why Inhibikase Therapeutics Inc stock could outperform in 2025 - Bộ Nội Vụ
Published on: 2026-01-14 00:17:08 - Bộ Nội Vụ
How Inhibikase Therapeutics Inc IQT0 stock reacts to stronger dollarSwing Trade & Growth Focused Investment Plans - Bộ Nội Vụ
Why Inhibikase Therapeutics Inc. stock attracts global investorsBest Sellers Snapshot & trail grip notes for mixed terrain - Улправда
How Inhibikase Therapeutics Inc. stock performs in weak economyMarket Weekly Review & Technical Entry and Exit Tips - Улправда
Is Inhibikase Therapeutics Inc. stock attractive for passive investorsPortfolio Update Report & Weekly Watchlist of Top Performers - ulpravda.ru
Can Inhibikase Therapeutics Inc. stock sustain institutional interestJuly 2025 PostEarnings & Stepwise Trade Execution Plans - Улправда
How Inhibikase Therapeutics Inc. (IQT0) stock reacts to stronger dollarWeekly Loss Report & Safe Entry Point Identification - Улправда
Can Inhibikase Therapeutics Inc. (IQT0) stock surprise with quarterly results2025 Key Lessons & Low Drawdown Trading Strategies - Улправда
Published on: 2026-01-08 18:28:15 - ulpravda.ru
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Is Inhibikase Therapeutics Inc. stock attractive for income investorsHealthcare Stock Analysis & Budget Investment Success - Улправда
Laser Focus WorldInhibikase Therapeutics, Inc.Common Stock (Nasdaq:IKT) Stock Quote - FinancialContent
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Critical Survey: Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
While Institutions Invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Benefited From Last Week's 24% Gain, Retail Investors Stood to Gain the Most - 富途牛牛
Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN) Head to Head Comparison - Defense World
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics (NASDAQ:IKT) Raised to “Strong-Buy” at HC Wainwright - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen - Defense World
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics (IKT): HC Wainwright & Co. Issues 'Buy' Rating | IKT Stock News - GuruFocus
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) price target decreased by 20.00% to 5.71 - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN
Contrasting Inhibikase Therapeutics (NYSE:IKT) and Sorrento Therapeutics (NASDAQ:SRNE) - Defense World
Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.00%
2.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):